A new analysis from the Pacific Research Institute Center for Medical Economics and Innovation estimates that North Carolina could save between $31.0 million and $62.8 million annually simply by giving greater priority to lower-cost biosimilars when they are already available.
As healthcare costs continue to rise, North Carolina lawmakers face a difficult and increasingly ongoing challenge: how to preserve quality health coverage for more than 750,000 teachers, state employees, retirees and their families without asking taxpayers to spend more or patients to pay higher premiums and out-of-pocket costs . . .
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Biosimilars offer NC rare opportunity to save millions without cutting care
Wayne Winegarden
A new analysis from the Pacific Research Institute Center for Medical Economics and Innovation estimates that North Carolina could save between $31.0 million and $62.8 million annually simply by giving greater priority to lower-cost biosimilars when they are already available.
As healthcare costs continue to rise, North Carolina lawmakers face a difficult and increasingly ongoing challenge: how to preserve quality health coverage for more than 750,000 teachers, state employees, retirees and their families without asking taxpayers to spend more or patients to pay higher premiums and out-of-pocket costs . . .
Click here to read the rest of the article
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.